EGTX — Egetis Therapeutics AB (publ) Share News
0.000.00%
Last trade - 00:00- SEK2.11bn
- SEK1.97bn
- SEK62.40m
Brief: Egetis Therapeutics Q2 Loss Narrows To SEK 33.2 Mln
Brief: Egetis Establishes Subsidiary In The U.S.
Brief: Egetis Receives Positive Opinion From European Medicines Agency
Brief: Egetis Raises SEK 180 Mln Through Rights Issue
Brief: Egetis Q1 Loss Widens To SEK 28.8 Mln
Brief: Egetis Receives Positive EMA Opinion For Orphan Designation Of Emcitate
Brief: Egetis Therapeutics Resolves On Rights Issue Of About SEK 180 Million
Brief: Egetis Therapeutics's Emcitate Gets Orphan Drug Designation From FDA
Brief: Egetis Therapeutics Q4 Loss Narrows To SEK 32.1 Mln
Brief: Egetis Secures Conditional Acceptance For Emcitate® As Brand Name In The U.S
Brief: Egetis Therapeutics: Demonstrating Treatment Effects On T3 Levels In MCT8-Deficiency Could Provide Basis For Marketing Approval For Emcitate In US
Brief: Egetis To Submit Authorisation Application For Emcitate
Brief: Egetis Therapeutics Gets Notice Of Allowance For New US Patent
Brief: Egetis Q3 Loss Narrows To SEK 22.5 Mln
Brief: Egetis Says New Data Confirms Safety Of Emcitate In MCt8 Deficiency
Brief: Egetis Receives Approval In Turkey For Compassionate Use Of Emcitate For MCT8 Deficiency
Brief: Egetis Therapeutics Chairman Acquires Shares
Brief: Egetis Therapeutics January March Quarterly Loss Narrows To SEK 19.3 Mln
Brief: Egetis Therapeutics Appoints Yilmaz Mahshid As New CFO